Iterum Therapeutics PLCNASDAQ:ITRM
- LAST PRICE1.8100
- TODAY'S CHANGE (%)0.0400 (2.2599%)
- Bid / Lots1.7600/ 15
- Ask / Lots1.8100/ 20
- Open / Previous Close1.8000 / 1.7700
- Day Range
- 52 Week Range
- Volume827,144
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ITRM |
|---|---|---|
| 09:32 ET | 23459 | 1.81 |
| 09:33 ET | 14037 | 1.765 |
| 09:35 ET | 14051 | 1.81 |
| 09:37 ET | 11556 | 1.8099 |
| 09:39 ET | 6301 | 1.79 |
| 09:42 ET | 7619 | 1.785 |
| 09:44 ET | 1539 | 1.785 |
| 09:46 ET | 9401 | 1.7801 |
| 09:48 ET | 14000 | 1.78 |
| 09:50 ET | 38632 | 1.7403 |
| 09:51 ET | 2504 | 1.745 |
| 09:53 ET | 7312 | 1.7405 |
| 09:55 ET | 3058 | 1.74 |
| 09:57 ET | 6102 | 1.74 |
| 10:00 ET | 2313 | 1.7392 |
| 10:02 ET | 400 | 1.7306 |
| 10:04 ET | 2027 | 1.735 |
| 10:06 ET | 1000 | 1.73 |
| 10:08 ET | 2507 | 1.72 |
| 10:09 ET | 1375 | 1.73 |
| 10:11 ET | 37757 | 1.705 |
| 10:13 ET | 3649 | 1.72 |
| 10:15 ET | 1861 | 1.73 |
| 10:18 ET | 3375 | 1.72 |
| 10:20 ET | 900 | 1.73 |
| 10:22 ET | 4428 | 1.74 |
| 10:24 ET | 25322 | 1.7487 |
| 10:26 ET | 3600 | 1.75 |
| 10:29 ET | 114 | 1.7473 |
| 10:33 ET | 615 | 1.745 |
| 10:36 ET | 600 | 1.7406 |
| 10:38 ET | 5000 | 1.79 |
| 10:44 ET | 1107 | 1.7524 |
| 10:45 ET | 1287 | 1.755 |
| 10:47 ET | 5521 | 1.7699 |
| 10:49 ET | 4326 | 1.7428 |
| 10:51 ET | 996 | 1.7501 |
| 10:54 ET | 200 | 1.75 |
| 10:58 ET | 600 | 1.75 |
| 11:00 ET | 8529 | 1.725 |
| 11:02 ET | 3076 | 1.7101 |
| 11:03 ET | 26146 | 1.73 |
| 11:07 ET | 2526 | 1.74 |
| 11:09 ET | 400 | 1.73 |
| 11:12 ET | 100 | 1.74 |
| 11:14 ET | 100 | 1.74 |
| 11:16 ET | 100 | 1.74 |
| 11:18 ET | 1100 | 1.735 |
| 11:20 ET | 200 | 1.735 |
| 11:21 ET | 10230 | 1.7399 |
| 11:23 ET | 810 | 1.735 |
| 11:25 ET | 381 | 1.735 |
| 11:27 ET | 5697 | 1.75 |
| 11:30 ET | 1759 | 1.74 |
| 11:32 ET | 100 | 1.74 |
| 11:34 ET | 652 | 1.74 |
| 11:38 ET | 250 | 1.7282 |
| 11:39 ET | 2150 | 1.76 |
| 11:41 ET | 200 | 1.74 |
| 11:45 ET | 425 | 1.745 |
| 11:50 ET | 7137 | 1.7355 |
| 11:52 ET | 100 | 1.74 |
| 11:54 ET | 2126 | 1.74 |
| 11:56 ET | 9366 | 1.75 |
| 11:57 ET | 1500 | 1.745 |
| 12:01 ET | 200 | 1.755 |
| 12:03 ET | 500 | 1.72 |
| 12:06 ET | 5198 | 1.74 |
| 12:10 ET | 365 | 1.7423 |
| 12:12 ET | 5515 | 1.75 |
| 12:14 ET | 1404 | 1.74 |
| 12:15 ET | 478 | 1.73 |
| 12:17 ET | 110 | 1.74 |
| 12:21 ET | 200 | 1.75 |
| 12:24 ET | 7299 | 1.745 |
| 12:28 ET | 120 | 1.7406 |
| 12:37 ET | 10749 | 1.766 |
| 12:39 ET | 10716 | 1.795 |
| 12:42 ET | 11832 | 1.78 |
| 12:44 ET | 499 | 1.7711 |
| 12:46 ET | 1098 | 1.7799 |
| 12:48 ET | 2280 | 1.76 |
| 12:50 ET | 1100 | 1.7601 |
| 12:51 ET | 113 | 1.79 |
| 12:53 ET | 390 | 1.79 |
| 12:57 ET | 8635 | 1.7708 |
| 01:00 ET | 200 | 1.77 |
| 01:02 ET | 1000 | 1.7626 |
| 01:04 ET | 1000 | 1.7741 |
| 01:06 ET | 3640 | 1.7858 |
| 01:08 ET | 394 | 1.78 |
| 01:11 ET | 2198 | 1.79 |
| 01:13 ET | 542 | 1.79 |
| 01:15 ET | 200 | 1.77 |
| 01:20 ET | 330 | 1.7809 |
| 01:22 ET | 4946 | 1.7798 |
| 01:24 ET | 9523 | 1.775 |
| 01:26 ET | 1100 | 1.77 |
| 01:27 ET | 100 | 1.775 |
| 01:29 ET | 5000 | 1.775 |
| 01:31 ET | 350 | 1.78 |
| 01:33 ET | 2516 | 1.775 |
| 01:36 ET | 300 | 1.778 |
| 01:38 ET | 4000 | 1.779705 |
| 01:40 ET | 500 | 1.77 |
| 01:42 ET | 100 | 1.778 |
| 01:44 ET | 100 | 1.775 |
| 01:45 ET | 1110 | 1.78 |
| 01:49 ET | 150 | 1.7701 |
| 01:54 ET | 407 | 1.7706 |
| 01:56 ET | 1259 | 1.78 |
| 02:02 ET | 999 | 1.78 |
| 02:03 ET | 118 | 1.78 |
| 02:05 ET | 1000 | 1.7772 |
| 02:07 ET | 261 | 1.78 |
| 02:14 ET | 8391 | 1.8 |
| 02:21 ET | 3800 | 1.81 |
| 02:23 ET | 300 | 1.815 |
| 02:25 ET | 800 | 1.8139 |
| 02:27 ET | 1300 | 1.815 |
| 02:30 ET | 100 | 1.815 |
| 02:34 ET | 4441 | 1.83 |
| 02:36 ET | 24573 | 1.835 |
| 02:38 ET | 100 | 1.8383 |
| 02:39 ET | 3244 | 1.8203 |
| 02:43 ET | 2100 | 1.8283 |
| 02:48 ET | 2700 | 1.8283 |
| 02:50 ET | 3600 | 1.83 |
| 02:52 ET | 3462 | 1.82 |
| 02:54 ET | 1700 | 1.81 |
| 02:57 ET | 22115 | 1.805 |
| 02:59 ET | 1466 | 1.8045 |
| 03:01 ET | 700 | 1.805 |
| 03:03 ET | 5254 | 1.7914 |
| 03:08 ET | 775 | 1.794 |
| 03:10 ET | 565 | 1.8 |
| 03:12 ET | 700 | 1.8 |
| 03:14 ET | 982 | 1.8 |
| 03:15 ET | 7965 | 1.805 |
| 03:17 ET | 5225 | 1.805 |
| 03:19 ET | 9625 | 1.795 |
| 03:21 ET | 3434 | 1.8 |
| 03:24 ET | 4304 | 1.7963 |
| 03:26 ET | 400 | 1.8 |
| 03:28 ET | 4531 | 1.805 |
| 03:30 ET | 1600 | 1.8007 |
| 03:32 ET | 5100 | 1.81 |
| 03:33 ET | 1219 | 1.82 |
| 03:35 ET | 6899 | 1.8042 |
| 03:37 ET | 1100 | 1.81 |
| 03:39 ET | 1200 | 1.807 |
| 03:42 ET | 637 | 1.81 |
| 03:44 ET | 4303 | 1.805 |
| 03:46 ET | 6800 | 1.8 |
| 03:48 ET | 700 | 1.79 |
| 03:50 ET | 300 | 1.79 |
| 03:51 ET | 5970 | 1.7997 |
| 03:53 ET | 10805 | 1.795 |
| 03:55 ET | 26420 | 1.8 |
| 03:57 ET | 5671 | 1.79 |
| 04:00 ET | 25682 | 1.81 |
Nov 21, 2024
Iterum Therapeutics Regains Full Nasdaq Compliance, from 8:30AM ET on Thursday Nov 21, 2024 by Dow Jones
8:30AM ET on Thursday Nov 21, 2024 by Dow Jones
Nov 14, 2024
Iterum Therapeutics Reports Third Quarter 2024 Financial Results, from 7:00AM ET on Thursday Nov 14, 2024 by Dow Jones
7:00AM ET on Thursday Nov 14, 2024 by Dow Jones*DJ Iterum Therapeutics 3Q Loss $6.09M >ITRM, from 7:00AM ET on Thursday Nov 14, 2024 by Dow Jones
7:00AM ET on Thursday Nov 14, 2024 by Dow Jones
Nov 11, 2024
Iterum Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024, from 8:00AM ET on Monday Nov 11, 2024 by Dow Jones
8:00AM ET on Monday Nov 11, 2024 by Dow Jones
Oct 28, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Iterum Therapeutics PLC | 41.1M | -0.9x | --- |
AN2 Therapeutics Inc | 40.0M | -0.7x | --- |
Exicure Inc | 39.9M | -8.1x | --- |
Rallybio Corp | 42.3M | -0.6x | --- |
vTv Therapeutics Inc | 42.7M | -3.2x | --- |
Xilio Therapeutics Inc | 39.2M | -0.5x | --- |
Company Information
Iterum Therapeutics plc is a clinical-stage pharmaceutical company. The Company develops differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. It is advancing its first compound, sulopenem, a novel penem anti-infective compound, in Phase III clinical development with an oral formulation. Sulopenem is a potent, thiopenem antibiotic delivered intravenously, which is active against bacteria that belong to the group of organisms known as gram-negatives and causes urinary tract and intra-abdominal infections. It has also developed sulopenem in an oral tablet formulation, sulopenem etzadroxil-probenecid. Sulopenem also has an IV formulation. Sulopenem has demonstrated potent in vitro activity against a variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics.
Contact Information
- Headquarters
- Fitzwilliam Court 1st Floor, Leeson Close, Dublin 2DUBLIN, Ireland D02 YW24
- Phone
- ---
- Fax
- ---
Executives
- Independent Chairman of the board
- Brenton Ahrens
- President, Chief Executive Officer, Director
- Corey Fishman
- Chief Financial Officer
- Judith Matthews
- Director
- Michael Dunne
- Independent Director
- Beth Hecht
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $41.1M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 22.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.34 |
EPS | $-2.00 |
Book Value | $-0.47 |
P/E Ratio | -0.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
